On Monday we learnt from Sir Patrick Vallance, the government’s Chief Scientific Adviser that Coronavirus will possibly under no circumstances disappear and a vaccine will not cease it absolutely. He also mentioned that ministers and professionals really should cease ‘over-promising’ and be realistic about the prospects of a vaccine and the probably timeline of 1, unlikely prior to spring next year.
He then echoed his earlier warnings and those of his colleague Professor Chris Whitty that the COVID-19 fight will be a long one, and it will be with us for superior.
So, from this should we assume there is no ‘silver bullet’ for COVID-19 infections?
What if there were a single treatment that:
could quit the infection in its tracks,
was anti-inflammatory controlling the immune system’s response to the infection and stopping it from overreacting dangerously,
in instances exactly where sufferers developed secondary bacterial infections in the lungs could supercharge antibiotics boosting their efficacy and eve,
was a repurposed drug currently proven as protected
was uncomplicated to make, scalable at the level necessary to make a distinction in the pandemic and was cost productive, then wouldn’t that be a thing we should all be having excited about?
Surely although no such ‘silver bullet’ game altering therapy exists? Just after all, the only therapies we hear about for COVID are these which President Trump took, which were either quite new, expensive and experimental or have a extremely narrow application to a distinct aspect of the illness.
Well, you heard it here first – such a ‘silver bullet’ remedy does exist today. It is called Nylexa®, from the smaller UK biotech organization NovaBiotics Ltd. It is active components have been safely employed in medicines that treat unrelated conditions for more than 30 years.
NovaBiotics discovered Nylexa’s possible advantages in COVID-19 following a decade of research in complicated to treat, drug-resistant infections, including the complex chest infections and inflammation linked with cystic fibrosis (CF) lung disease. In March they applied for a £1m grant from Innovate UK (representing the government) to start clinical research. That grant was ultimately awarded earlier this month, and the government are now thinking about whether or not to contain Nylexa on two separate NHS platform research.
But why, I hear you ask, if this is so fantastic have we not heard about it just before? Why are the government and the press not shouting about this from the rooftops? Why is this not becoming demanded by clinicians desperate for productive remedies for their sufferers?
https://kenethnumen.wixsite.com/healthandfitnesss am afraid to say, it all boils down to income. Small biotech firms uncover it hard to get attention as they don’t have the resources accessible to their bigger greater funded rivals. The names we read about often when it comes to ground breaking new treatments are invariably substantial multi-national pharmaceutical firms with deep pockets and huge budgets to promote their own particular wares. They make sure their drugs get the expected interest. NovaBiotics is a smaller private company funded by a group of loyal and supportive shareholders so regrettably never have the resources to compete for attention with the massive boys.
Which is why this situation is so frustrating. In mitigating the overall health consequences of contracting COVID-19, Nylexa® could boost public self-confidence of living with the virus for the longer term and potentially enable a higher degree of normality to return to the way in which we live, benefiting the economy straight in addition to easing COVID-19’s burden on the NHS and healthcare systems globally. Yet finding people in positions of influence to take notice amongst all the other individuals competing for their attention is very hard certainly.
It is reported that there are thousands of prospective COVID-19 therapies in clinical trials across the planet. I would challenge any person to show me 1 which has the similar prospective for optimistic impact as Nylexa®, but this is not currently part of any trial, in spite of its impeccable credentials. So come on UK Government, and ministers, get your finger out and get this drug into trials right away. The sooner it gets tested, the sooner it can be used to help sort out the mess the pandemic has triggered to all our lives.
About NovaBiotics Ltd
NovaBiotics Ltd is a clinical-stage biotechnology enterprise focused on the design and style and development of 1st-in-class therapies for hard-to-treat, medically unmet infectiousdiseases brought on by bacteria and fungi and respiratory conditions like cystic fibrosis and COVID-19.
A top innovator in the anti-infectives space, the Company’s robust technology and company model has been validated through prosperous improvement, from notion to late stage clinical development, of its most advanced product candidates. In addition to the lead Nylexa® programme and the Company’s other late-stage assets (Lynovex® for cystic fibrosis, NP213/Novexatin® for onychomycosis), NovaBiotics has generated a robust pipeline of earlier stage, high-value drug candidates including NP339 (Department of Health and Social Care funded programme) for life threatening, drug resistant invasive fungal illness and NP432 for multi- drug resistant bacterial infections.